tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile
PremiumRatingsPromising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile
2M ago
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating
Premium
Ratings
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating
2M ago
Arcellx reports Q2 EPS (94c), consensus ($1.03)
Premium
The Fly
Arcellx reports Q2 EPS (94c), consensus ($1.03)
2M ago
Arcellx initiated with a Buy at Citi
PremiumThe FlyArcellx initiated with a Buy at Citi
3M ago
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
Premium
Ratings
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment
3M ago
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
Premium
Ratings
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position
3M ago
Arcellx Inc Holds Annual Stockholders Meeting
PremiumCompany AnnouncementsArcellx Inc Holds Annual Stockholders Meeting
4M ago
Arcellx, Inc. Reports Q1 2025 Financial Results
Premium
Company Announcements
Arcellx, Inc. Reports Q1 2025 Financial Results
4M ago
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst
Premium
Ratings
Arcellx Inc’s Anito-cel Shows Promising Results in Phase 2 Trial, Earning Buy Rating from Analyst
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100